Kendall M. Mohler

Dr. Kendall M. Mohler serves as NEUVOGEN’s science advisor and operational board member. Dr. Mohler is Chief Development Officer at Accelerator Life Science Partners, bringing more than three decades of experience in the biopharmaceutical industry, including several years of leading scientific research and development teams in the areas of autoimmune disease, inflammation, and oncology. He works closely with all Accelerator Life Science Partner portfolio companies, where he provides oversight over key scientific research and product development activities. Prior to joining Accelerator, Dr. Mohler served as Senior Vice President of Research and Chief Scientific Officer of Juno Therapeutics Inc. He also served as Chief Science Officer at ZetaRx, a predecessor company that was acquired by Juno. Prior to Juno, Dr. Mohler co-founded Trubion Pharmaceuticals Inc., and served as their Chief Scientific Officer and Senior Vice President, overseeing the development of several first-in-class product candidates and supporting several partnerships with global pharmaceutical companies. Prior to Trubion, Dr. Mohler served as Vice President of Biological Sciences of Immunex Corporation, where he led research and development activities in the areas of transplantation, autoimmunity & inflammation. He was the preclinical lead for Enbrel’s® (etanercept) research and development activities and successfully shepherded the product from inception of the development program through BLA approval. Dr. Mohler has published more than 35 manuscripts and is a named inventor on multiple issued patents and pending patent applications. He received a PhD in Immunology from the University of Texas Health Science Center and a BS from the University of Kansas.